AusBiotech

Bioxyne has secured a two-year supply agreement worth up to $50 million with German pharmaceutical company ADREXpharma GmbH, a move the Australian firm says will give it a defined pathway into Europe and near-term revenue visibility.

Amplia Therapeutics and the Australia New Zealand Gynaecological Oncology Group have launched a new investigator-initiated clinical study to test the FAK inhibitor narmafotinib in combination with standard chemotherapy.

Neurizon Therapeutics has appointed a new Chief Financial Officer to strengthen its leadership as it prepares to advance its lead drug candidate, NUZ 001, through late-stage clinical trials and to build readiness for future commercialisation.

Gordon Naylor, who stepped into CSL's interim chief executive role in February, has completed a 90-day review and set out a plan to accelerate the company’s transformation.

BCAL Diagnostics has announced the appointment of Anne Louise Arnett as Chief Executive Officer, effective 1 June 2026, as the company accelerates the commercial rollout of its early cancer detection products.

Moderna has opened applications for the 2026 Moderna Australia Fellowship, a program that will fund and mentor early-career Australian scientists for two years as they pursue mRNA research and innovation.

PYC Therapeutics has dosed the first patient in a Phase 1b Multiple Ascending Dose study testing PYC-003 in people with polycystic kidney disease.

Noxopharm has engaged a global clinical research organisation to strengthen its US regulatory strategy and prepare for a pre-Investigational New Drug meeting with the US Food and Drug Administration.

Algorae Pharmaceuticals has announced that it has executed an agreement with Torrent Pharmaceuticals to commercialise two prescription molecules in Australia and New Zealand.

The board confirmed the promotion from her role as Chief Operating Officer, which she took up in 2023 after more than 18 years at Hexima, where she helped advance that company's lead drug candidate through preclinical and clinical development.

Entropy Neurodynamics has reported Phase 2a results suggesting a potential new direction for patients with treatment-resistant irritable bowel syndrome.

Botanix Pharmaceuticals has announced the promotion of Paul Seaback to Chief Operating Officer, a move the commercial dermatology company said will strengthen day-to-day operations and drive strategic growth across its Philadelphia and Phoenix businesses.